SUMMIT, N.J., June 12, 2025 /PRNewswire/ -- Vascarta Inc., a biopharmaceutical company committed to advancing innovative therapies for underserved patient populations, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead drug...
Hence then, the article about vascarta receives fda orphan drug designation for vasceptor in the treatment of sickle cell disease was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Vascarta Receives FDA Orphan Drug Designation for Vasceptor® in the Treatment of Sickle Cell Disease )
Also on site :
- Best Accounting Software for UK Small Business (January 2026): Sage Recognised as the Leading Solution for Managing Finances by Consumer365
- The Dollar Is Facing an End to Its Dominance
- Billion-Dollar Data Centers Are Taking Over the World